associated with a reduced risk of remission and remission/LLDAS; lower socioeconomic status was associated with a reduced risk of remission. A medium prednisone dose was associate with an increased risk of remission/LLDAS.

THE EFFECT OF ADDING CURCUMIN ON VITAMIN D3 SUPPLEMENTATION ON THE DISEASE ACTIVITIES AND FATIGUE DEGREE IN SLE PATIENTS WITH HYPOVITAMIN D

Background and aims Vitamin D has important roles in the regulation of the immune system in Lupus. Seventy percent of lupus patients in Indonesia are experienced hypovitamin D. Curcumin is a natural VDR ligand and has sinergic effect with vitamin D. This study was aimed to determine the effect of adding curcumin on vitamin D supplementation on the degree of disease activity and degree of fatigue, in SLE patients with hypovitamin D.

Methods This was a randomised controlled trial, double blind study. Forty SLE patients with hypovitamin D were studied, that randomizied into two groups: 20 patients (supplementation group) received vitamin D (cholecalciferol 1200 IU daily) with curcumin 20 mg (three times daily); and 20 patients (placebo group) was given vitamin D (cholecalciferol 1200 IU daily) and placebo (3 times daily), for 3 months. Disease activity is determined by the SLEDAI scores and the degree of fatigue is determined by the FSS (Fatigue Severity Scale).

Results After supplementation for 3 months, this study showed that decreased of SLEDAI score in the supplementation group was greater than the placebo group. The decreased of FSS in the supplementation group was also greater than the placebo group.

Conclusions Adding curcumin on vitamin D supplementation, decreased SLEDAI scores and FSS greater than vitamin D supplementation plus placebo in SLE patients with hypovitamin D.

THE EFFECT OF ADDING CURCUMIN ON VITAMIN D3 SUPPLEMENTATION ON ANTI-DSDNA LEVELS AND PROTEINURIA, IN SLE PATIENTS WITH HYPOVITAMIN D

Background and aims Vitamin D has important roles in the regulation of the immune system in Lupus. Seventy percent of lupus patients in Indonesia are experienced hypovitamin D. Curcumin is a natural VDR ligand and has sinergic effect with vitamin D. This study was aimed to determine the effect of adding curcumin on vitamin D supplementation on anti-dsDNA serum levels and proteinuria, in SLE patients with hypovitamin D.

Methods This was a randomised controlled trial, double blind study. Forty SLE patients with hypovitamin D were studied, that randomizied into two groups: 20 patients (supplementation group) received vitamin D (cholecalciferol 1200 IU daily) with curcumin 20 mg (three times daily); and 20 patients (placebo group) was given vitamin D (cholecalciferol 1200 IU daily)
and placebo (3 times daily), for 3 months. Anti-ds DNA serum levels were measured by ELISA and urine protein were measured by urine albumin creatinine ratio (UACR).

**Results** After supplementation for 3 months, this study showed that decreased of anti-dsDNA serum levels in the supplementation group was significantly greater than in the placebo group. The decreased of UACR in the supplementation group was also significantly greater than the placebo group.

**Conclusions** Adding curcumin on vitamin D supplementation can decrease anti-dsDNA serum levels and proteinuria greater than vitamin D supplementation plus placebo in SLE patients with hypovitamin D.

---

**THE EFFECT OF ADDING CURCUMIN ON VITAMIN D3 SUPPLEMENTATION ON CYTOKINES BALANCE, IN SLE PATIENTS WITH HYPOVITAMIN D**

1CS Wahono*, 1I Saveria, 1CD Setyorini, 2D Wahyuni, 2K Handono, 1H Kalim. 1Universitas Brawijaya/Saiful Anwar Hospital, Internal Medicine, Malang, Indonesia; 2Universitas Brawijaya/Saiful Anwar Hospital, Clinical Pathology, Malang, Indonesia

10.1136/lupus-2017-000215.258

**Background and aims** Vitamin D has important roles in the regulation of the immune system in Lupus. Seventy percent of lupus patients in Indonesia are experienced hypovitamin D. Curcumin is a natural VDR ligand and has sinergic effect with vitamin D. This study was aimed to determine the effect of adding curcumin on vitamin D supplementation on IFN-γ/IL-4 ratio and IL-17/TGF-β ratio, in SLE patients with hypovitamin D.

**Methods** This was a randomised controlled trial, double blind study. Forty SLE patients with hypovitamin D were studied, that randomised into two groups: 20 patients (supplementation group) received vitamin D (cholecalciferol 1200 IU daily) with curcumin 20 mg (three times daily); and 20 patients (placebo group) was given vitamin D (cholecalciferol 1200 IU daily) and placebo (3 times daily), for 3 months. Cytokines serum levels (IFN-γ, IL-4, IL-17, TGF-β) were measured by ELISA.

**Results** After supplementation for 3 months, this study showed that decreased of IFN-γ/IL-4 ratio in the supplementation group was significantly greater than in the placebo group. The decreased of IL-17/TGF-β ratio in the supplementation group was also significantly greater than the placebo group.

**Conclusions** Adding curcumin on vitamin D supplementation can decrease IFN-γ/IL-4 ratio and IL-17/TGF-β ratio than vitamin D supplementation plus placebo in SLE patients with hipovitamin D.

---

**THE EFFECT OF VITAMIN D3 SUPPLEMENTATION ON THE ANTI-DSDNA LEVELS AND URINE PROTEIN IN SLE PATIENTS WITH HYPOVITAMIN D**

1H Susianti*, 1CS Wahono, 1ST Priyantoro, 1K Handono, 1H Kalim. 1Faculty of Medicine Brawijaya University/Dr. Saiful Anwar General Hospital, Internal Medicine, Malang, Indonesia; 2Faculty of Medicine Brawijaya University/Dr. Saiful Anwar General Hospital, Clinical Pathology, Malang, Indonesia

10.1136/lupus-2017-000215.259

**Background and aims** Vitamin D has important role in the regulation of the immune system in Lupus. Seventy one percent of lupus patients experienced hypovitamin D in Indonesia. This study was aimed to determine the effect of vitamin D supplementation on the degree of disease activity and degree of fatigue in SLE patients with hypovitamin D.

**Methods** Thirty nine SLE patients with hypovitamin D were studied, that randomised into two groups: 20 patients was given vitamin D and 19 patients received placebo for 3 months. Disease activity is determined by the SLEDAI scores and the degree of fatigue is determined by the FSS (Fatigue Severity Scale).

**Results** This study showed that supplementation of vitamin D 1200 IU per day increased 6.55±1.27 ng/cc of 25 (OH) D. The decreased of SLEDAI scores in the supplementation group were greater than the placebo group (6.45±3.07 vs 0.17 ±1.63), p=0.000. The decreased of Fatigue Severity Scale in the supplementation group also greater than the placebo group (2.27±0.73 vs 0.005±0.62), p=0.000.

**Conclusions** Vitamin D supplementation plays a role on improving the activity of the disease (SLEDAI score) and the condition of fatigue (FSS) in SLE patients with hypovitamin D.

---

**THE EFFECT OF VITAMIN D3 SUPPLEMENTATION ON THE ANTI-DSDNA LEVELS AND URINE PROTEIN IN SLE PATIENTS WITH HYPOVITAMIN D**

1J Meng. 1Beijing Chao-Yang Hospital- Capital Medical University, Department of Rheumatology and Immunology, Bei Jing, China

10.1136/lupus-2017-000215.261

**Background and aims** Vitamin D has important role in the regulation of the immune system in Lupus. Seventy one percent of lupus patients in Indonesia experienced hypovitamin D. This study was aimed to determine the effect of vitamin D supplementation on the levels of anti ds dna and degree of urine protein in lupus patients with hypovitamin D.

**Methods** Thirty nine SLE patients with hypovitamin D were studied, that randomized into two groups: 20 patients was given vitamin D and 19 patients received placebo for 3 months. Anti-ds DNA levels were measured by ELISA and urine protein were measured by dipstick method.

**Results** Anti-dsDNA levels in the supplement group before and after giving vitamin D were 226.84±82.11 vs 191±72.55 (p=0.00), and the placebo group were 233.69±66.52 vs 227.72±61.21 (p=0.077). The degree of urine protein in the supplement group before and after treatment were 24 vs 12 U/ml (p=0.003) and the placebo group were 16 vs 10 U/ml (p=0.070).

**Conclusions** Vitamin D supplementation plays a role on decreasing the levels of anti ds-DNA and urine protein in SLE patients with hypovitamin D.